Małgorzata Kęsik-Brodacka, PhD

PhD in Biochemistry,
An Assistant Professor at the Department of Bioengineering at the Institute of Biotechnology and Antibiotics, a head of Biochemistry Laboratory II.
A graduate of the University of California, Berkeley – Walter A. Haas School of Business TOP 500 Innovators Program, Innovation, Business Management, Commercialization, and postgraduate studies, i.e. “Innovation Manager”, the Warsaw School of Economics, and “Research Project Management and Research Result Commercialization” at the Łódź University of Technology.
She internship at the European Patent Office (EPO) on the patentability of inventions in the EPO. The internship organized by the EPO, Munich, Germany – „Praktika Intern-Ship”.
She has also acquired his experience as a Postdoctoral Scholar at the Department of Molecular Biology and Microbiology Case Western Reserve University, Cleveland OH, USA.
Małgorzata Kęsik-Brodacka is a co-author of technology of generating analogues of recombined human insulin with modified effect. The technology has been commercialized.
Number of awarded international and domestic patents: 13
Number of international and domestic patent applications: 11
She has undergone several specialist courses in the field bioinformatics, molecular biology, biotechnology, proteomics and project management.
Małgorzata Kęsik-Brodacka is a member of the Top500 Innovators Association (a member of the Audit Committee);, the Biotechnology Committee at the Polish Academy of Sciences, the Federation of European Biochemical Societies (FEBS), the Polish Biochemical Society, the Polish Vaccine Consortium.
Languages: English and French.